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Abstract
Efficacy and safety of direct oral anticoagulants (DOACs) for preventing primary and recurrent venous thromboembolism (VTE)
in patients with cancer remain unclear. In this study, we conducted a systematic review to summarize the most up-to-date
evidence from randomized controlled trials (RCTs). Our primary outcomes included the benefit outcome (VTE) and safety
outcome (major bleeding). A random-effects model was used to pool the relative risks (RRs) for data syntheses. The Grading of
Recommendations Assessment, Development and Evaluation tool was used to evaluate the quality of the entire body of evidence
across studies. We included 11 RCTs with a total of 3741 patients with cancer for analyses. The DOACs were significantly related
with a reduced risk of VTE when compared with non-DOACs: RR ¼ 0.77, 95% confidence interval [CI]: 0.61-0.99, P ¼ .04.
Nonsignificant trend towards a higher risk of major bleeding was found in DOACs: RR ¼ 1.28 95% CI: 0.81-2.02, P ¼ .29. The
quality of the entire body of evidence was graded as moderate for risk of VTE, and low for risk of major bleeding. To summarize,
DOACs were found to have a favorable effect on risk of VTE but a nonsignificant higher risk of major bleeding compared with
non-DOACs in patients with cancer. The safety effect of DOACs in patients with cancer requires further evaluation in adequately
powered and designed studies.
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Background
Venous thromboembolism (VTE), including deep vein throm-
bosis (DVT) and pulmonary embolism (PE), occurs in up to
15% of patients with cancer during the course of their dis-
ease.1,2 Venous thromboembolism is found to be the second
leading cause of death after malignancy itself.3 Compared with
those without cancer, the risk of recurrent VTE is at least 2 fold
higher in patients with cancer.4 Although anticoagulant therapy
is recommended to prevent VTE, the increased risk of
anticoagulant-induced bleeding is however of significant con-
cern in patients with cancer.
The use of low molecular weight heparin (LMWH) for at
least 6 months is currently the standard treatment for acute VTE
in patients with cancer, due to its better effect on preventing
VTE and similar bleeding profile when compared with vitamin
K antagonists (VKAs).5,6 Given that LMWH is administrated
subcutaneously, VKAs are an acceptable alternative for long-
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term prophylaxis due to patients’ preference or the unavailability
of LMWH.5 Recently the direct oral anticoagulants (DOACs)
have been used to prevent VTE in patients with cancer with a
promising benefit–harm profile reported. Meta-analyses based
on findings from randomized controlled trials (RCTs) have
reported conflicting results, as follows: (1) DOACs had superior
efficacy and safety over VKAs, though nonsignificantly, and (2)
DOACs are equally effective and safe when compared with
LMWH.7-9 Nevertheless, some studies also reported a lower risk
of VTE and an increased risk of bleeding in DOACs than in
VKAs or LMWH,10,11 while others indicated reduction in risk of
major bleeding in DOACs.12,13
Given the inconsistent findings in the literature, and espe-
cially given more contemporary RCTs published, we aimed to
systematically summarize the most up-to-date evidence from
RCTs to assess the efficacy and safety of DOACs compared
with conventional therapy (VKAs and LMWH) for preventing
primary and recurrent cancer-associated VTE. Results of this
systematic review and meta-analysis may help clarify the ben-
efit–harm profile of DOACs in patients with cancer.
Methods
We conducted this study by following the recommendations
from the Cochrane Handbook of Systematic Reviews14 and
reported results based on the PRISMA (Preferred Reporting
Items for Systematic Reviews and Meta-Analyses) guideline.15
We registered our study in the Prospective Register of Ongoing
Systematic Reviews (identifier: CRD42018109053)
Search Strategy
We searched the following electronic databases to identify eli-
gible RCTs: MEDLINE, CINAHL and EMBASE from incep-
tion to October 28th, 2018. We used descriptors including
synonyms for trial, VTE or bleeding, and DOACs in the search
(detailed terms for search were presented in Supplemental
Table 1). Reference lists of included studies and other review
or editorial articles were also searched for relevant reports. No
language restriction was used. We also searched the annual
meeting abstracts up to October 2018 for relevant unpublished
and ongoing studies from the American Society of Hematology
and American Society of Clinical Oncology.
Study Eligibility Criteria
In this systematic review, we focused on patients with cancer
(ie, with history of cancer or with active cancer) who used
DOACs, VKAs or LMWH for preventing primary or recurrent
VTE. Phase III RCTs comparing the efficacy and safety of
DOACs with VKAs or LMWH for prevention or treatment of
cancer-associated VTE were included. The DOACs we
assessed included direct thrombin inhibitor (dabigatran) and
factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban).
Outcomes
Primary outcomes included the benefit outcome (VTE) and
safety outcome (major bleeding). Secondary outcome included
clinically relevant nonmajor bleeding and all-cause mortality.
All the outcome measurements collected were defined as from
the individual included studies.
Data Extraction
Two reviewers (J.Z. and X.Z.) independently screened and
chose potential eligible studies, with the agreement measured
by the k statistics.16 Disagreement was resolved by discussion
between the 2 reviewers, and if no consensus could be reached,
a third reviewer (G.L.) was involved to make a final decision.
The 2 reviewers used data extraction forms to extract data
independently. Data collected included study design, charac-
teristics of patients, details on interventions and follow-ups,
outcome measures, and treatment effect estimates.
Quality Assessment of Individual Included Study
We used the Risk of Bias assessment tool from the Cochrane
Collaboration to evaluate the quality of individual included
study, where the tool included domains of sequence genera-
tion, allocation concealment, blinding, incomplete outcome
data, selective outcome reporting and other issues.14 Studies
were rated as low-risk-of-bias if low risks were found in all the
domains, while studies were classified as high-risk-of-bias if
high risks were found in one or more domains.
Statistical Analyses
We used the random-effects model to pool the relative risks
(RRs) from the RCTs for data syntheses. Some studies may
report data on hazard ratios (HRs), rather than RRs, then we
calculated the crude RRs from the contingency tables for these
studies. Results were presented as the pooled RRs with 95%
confidence intervals (CIs).
We used the I2 statistic to evaluate the heterogeneity, with
an I2 > 50% or P value <.1 considered as indicating significant
heterogeneity. To account for potential heterogeneity, we per-
formed 5 a priori subgroup analyses by: (1) different com-
parators (ie, comparing DOACs with VKAs, and comparing
DOACs with LMWH); (2) different follow-up time (ie,  6
months vs > 6 months); (3) disease status (ie, active cancer vs
history of cancer); (4) different VTE profiles (DVT vs PE);
and (5) different purposes of VTE prevention (primary pre-
vention vs recurrent VTE prevention). We used the test by
Borenstein et al to assess whether the subgroup differences
were significant,17 and used the Altman and Bland method to
explore whether subgroup results significantly differed from
the main findings.18 Two predefined sensitivity analyses were
conducted by: (1) excluding high-risk-of-bias studies; and (2)
excluding trials that provided subgroup analysis data on
patients with cancer (ie, excluding those RCTs that
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randomized heterogeneous populations, rather than patients
with cancer only).
Publication Bias Assessment
Funnel plots were drawn to detect the potential publication
bias, using visual inspection for signs of asymmetry, Egger
regression test, and Begg rank correlation test.14
Quality Assessment for the Entire Body of Evidence
Across Studies
We used the Grading of Recommendations Assessment, Devel-
opment and Evaluation tool to evaluate the quality of the entire
body of evidence across studies for primary outcomes.19 The
quality of the entire body of evidence across studies can be
categorized as high, moderate, low, or very low. While synthe-
sized evidence from RCTs is originally rated as high, several
reasons can downgrade the quality including limitations in
study design, imprecision of study results, unexplained hetero-
geneity or inconsistency of results, indirectness of evidence,
and probability of publication bias.19 Two independent inves-
tigators (J.Z. and X.Z.) conducted the quality assessment first; a
group discussion was subsequently performed to reach a con-
sensus on the quality rating for the entire body of evidence in
this systematic review.
Results
There was a total of 3027 records included for screening. After
removing duplicates and screening titles and/or abstracts,
we evaluated 79 full-text articles for further eligibility judg-
ment (k ¼ 0.85, 95% CI: 0.79-0.91). We included 11 eligible
RCTs20-30 for quantitative syntheses (Supplemental Figure 1
shows the study selection process).
Study and patient characteristics are summarized in Table 1.
The included trials were published form year 2009 to 2018,
with 7 comparing DOACs with VKAs 20,21,23-26,30 and the
other 4 comparing DOACs with LMWH.22,27-29 Two RCTs
were conducted to prevent primary VTE,28,29 while the other
9 were for prevention of recurrent VTE. A total of 3741
patients (1897 in DOACs, 1844 non-DOACs) with cancer were
included for analyses. The mean age varied from 54 to 71
years. Follow-up periods ranged from 3 to 36 months. Regard-
ing study quality assessment, the domains of included trials
were rated as high in general. However, some studies were
graded as high-risk-of-bias due to lack of blinding of partici-
pants and personnel22-24,27 (Supplemental Figure 2). Informa-
tion on patients with cancer was from subgroup data in the
majority (9/11, 82%) of included trials, while only 2 trials
specifically randomized all the patients with cancer.22,27 We
extracted such subgroup data from their post-hoc publications
for RE-COVER I and II studies,31 EINSTEIN DVT and PE
studies,32 MAGELLAN and ADOPT studies,33 Hokusai-VTE
study,34 and AMPLIFY study.35 Subgroup data for RE-MEDY
study were retrieved from both the main report20 and commu-
nications with the authors.
Figure 1 shows the synthesized treatment effect estimate
comparing DOACs with non-DOACs for risk of VTE in
patients with cancer. The DOACs were found to be signifi-
cantly related with reduced risk of VTE: RR ¼ 0.77, 95%
CI: 0.61-0.99, P ¼ .04. No significant heterogeneity was
observed. The risk of major bleeding in DOACs compared with
non-DOACs in patients with cancer was reported in Figure 2.
Nonsignificantly higher risk of major bleeding was found with
DOACs, with a RR of 1.28 (95% CI: 0.81-2.02, P ¼ .29). The
heterogeneity was nonsignificant (I2¼ 30%, P ¼ .19). Regard-
ing secondary outcomes, DOACs were nonsignificantly related
with increased risk of clinically relevant nonmajor bleeding
(RR ¼ 1.13, 95% CI: 0.66-1.95) and all-cause mortality
(RR¼ 1.02, 95%CI: 0.89-1.18; Supplemental Figures 3 and 4).
Table 2 displays results from subgroup and sensitivity anal-
yses. Unlike the main analysis result, DOACs were nonsigni-
ficantly related with decreased risk of major bleeding when
pooling studies that compared DOACs with VKAs (RR ¼
0.72, P ¼ .31), and that focused on patients with history of
cancer (RR ¼ 0.57, P ¼ .17). No significant subgroup effect or
no significant difference between subgroup results and main
findings was observed. Sensitivity analyses yielded similar
RRs but wider 95% CIs to the main analyses. No evidence of
publication bias was detected when comparing DOACs with
non-DOACs in risk of VTE and major bleeding (Supplemental
Figures 5 and 6), with all the P values of >.05 from Egger and
Begg tests. The quality of the entire body of evidence was
graded as moderate for risk of VTE due to limitation in study
design when the majority of data were from subgroup analyses,
and graded as low for risk of major bleeding due to limitation in
study design and imprecision of study results (Supplemental
Table 2).
Discussion
In this study, we summarized all the available evidence from
RCTs to investigate efficacy and safety of DOACs compared
with conventional therapy in patients with cancer. A favorable
effect on risk of VTE was found in DOACs; however, the latter
had a trend towards increased risk of major bleeding when
compared with non-DOACs. Given the quality of the entire
body of evidence, the choice of DOACs in patients with cancer
for prevention and treatment of VTE still warrants further clin-
ical research.
We assessed the comparative efficacy and safety between
DOACs and non-DOACs (Figures 1 and 2) and tried to explore
whether results were robust across subgroup and sensitivity
analyses (Table 2). Similar to the main results, DOACs were
related with lower risk of VTE when compared with either
VKAs or LMWH. The DOACs seemed to have a favorable
benefit–harm profile than VKAs, which was consistent with
previous studies.7,13,36 Nevertheless, DOACs were found to
significantly increase risk of major bleeding when compared
with LMWH. This finding was consistent when pooling all the
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Figure 1. The forest pthe lot of the risk of VTE in patients with cancer.
Figure 2. The forest plot of the risk of major bleeding in patients with cancer.
Table 2. Result of Subgroup and Sensitivity Analyses for Comparison between DOACs and non-DOACs.
Analysis
VTE Major Bleeding
Number of
Studies/Patients
Pooled RR
(95% CI), P Value
Number of
Studies/Patients
Pooled RR
(95% CI), P Value
Subgroup analysis
Different non-DOACs
DOACs vs VKAs 7/1294 0.69 (0.42, 1.15), .16 6/1145 0.72 (0.39, 1.35), .31
DOACs vs LMWH 4/2447 0.80 (0.51, 1.26), .34 4/2447 1.85 (1.22, 2.80), .003
Follow-up time
6 months 3/1165 1.16 (0.73, 1.83), .53 3/1162 1.12 (0.28, 4.55), .87
>6 months 8/2576 0.66 (0.49, 0.88), .005 7/2430 1.26 (0.78, 2.03), .34
Type of cancer
Active cancer 8/2941 0.63 (0.49, 0.81), <.001 8/2746 1.07 (0.60, 1.92), .82
History of cancer 4/1594 0.50 (0.23, 1.07), .07 4/1601 0.57 (0.25, 1.28), .17
Different VTE profile
DVT 2/1452 0.53 (0.32, 0.87), .01b 0/0 -a
PE 2/1452 0.79 (0.40, 1.55), .49b 0/0 -a
VTE prevention
Primary prevention 2/995 0.82 (0.50, 1.32), .39b 2/995 2.32 (0.96, 5.59), .06b
Recurrent VTE prevention 9/2746 0.66 (0.49, 0.88), .004 8/2597 1.16 (0.72, 1.88), .54
Sensitivity analysis
Including low-risk-of-bias studies only 4/662 0.74 (0.39, 1.42), .37 3/519 1.03 (0.44, 2.40), .95
Excluding trials that only provided subgroup analysis data 2/1452 0.61 (0.42, 0.89), .01b 2/1452 1.75 (1.10, 2.77), .02b
Abbreviations: CI, confidence interval; DOACs, direct oral anticoagulants; DVT, deep-vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary
embolism; RR, relative risk; VKAs, vitamin K antagonists; VTE, venous thromboembolism.
aNo meta-analysis conducted due to insufficient studies or data available.
bFixed-effects model used due to only two studies included for analyses.
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available data (RR ¼ 1.85, P ¼ .003) or when using data from
trials22,27 that specifically randomized all the patients with
cancer (RR ¼ 1.75, P ¼ .02; Table 2). The difference in bleed-
ing risk between DOACs and LMWH may be due to different
drug interaction in patients with cancer who were commonly
taking anticancer agents and other co-medications. Since
LMWH was administrated subcutaneously, its plasmatic con-
centration and pharmacokinetics may be less influenced by
drug interaction than DOACs that were orally consumed.
Chemotherapy-related vomiting, different cancer severity and
stages, and different outcome definitions/measures, may also
interpret the difference in risk of major bleeding. Moreover,
individual DOACs (dabigatran, apixaban, rivaroxaban, and
edoxaban) may yield different benefits and safety effects. For
example, in a head-to-head comparison between 3 individual
DOACs (dabigatran, apixaban, and rivaroxaban) for stroke pre-
vention in atrial fibrillation based on evidence from observa-
tional studies, apixaban was associated with the most favorable
safety profile (risk of major bleeding).37 Unfortunately, the
small number of included studies precluded us from further
exploring the difference in risk of major bleeding between
DOACs and LMWH (Table 1).
The purpose of this review was to show a general picture
regarding the effect of DOACs in patients with cancer in clin-
ical practice. We tried to explore all sources of heterogeneity
and test whether the heterogeneity was significant. Some
results were different between subgroups; however all the sub-
group effects were not significant (Table 2). Moreover, the
overall pooled analyses did not find significant heterogeneity
(Figures 1 and 2). Therefore we synthesized all the data to
provide a simple and straightforward summary with extreme
caution for result interpretation and clinical implication.
Our study included 11 RCTs and a total of 3741 patients
with cancer for analyses, which is the largest population size
based on the latest available evidence. Brunetti et al reported
that after pooling data on 1952 patients with cancer from 9
RCTs, DOACs produced a favorable effect on both risk of VTE
(odds ratio [OR] ¼ 0.79, P ¼ .96) and major bleeding (OR ¼
0.96, P ¼ .10) compared with non-DOACs. However it only
used all the subgroup data and did not include the 2 trials that
randomized all patients with cancer.22,27 Data from subgroup
analyses in trials, especially for those from post-hoc publica-
tions without a priori hypotheses, should be interpreted with
caution due to their weak credibility.38 Posch et al conducted a
network meta-analysis of RCTs to compare DOACs with non-
DOACs in patients with cancer.9 They reported favorable ben-
efit–harm profile in DOACs compared with VKAs based on the
data from direct comparisons in 6 RCTs. However, when they
performed an indirect network comparison by using data from
DOACs versus VKAs and from LMWH versus VKAs, they
found a higher risk of VTE (RR¼ 1.08) but lower risk of major
bleeding (RR ¼ 0.67) in DOACs compared with LMWH,
which conflicted with our findings. Likewise, the evidence
strength of indirect comparisons should be largely weakened;
such evidence is usually used to generate hypothesis and to
advocate direct comparative evidence for validation.14,39 By
contrast, another systematic review comparing DOACs with
LMWH only included the 2 trials that randomized all patients
with cancer.10 It reported significantly higher risk of major
bleeding than LMWH (RR ¼ 1.74, P ¼ .03), but lower risk
of VTE (RR¼ 0.65, P¼ .06), which was similar to our results.
Our study has some strengths. We summarized all the evi-
dence to systematically assess the comparative effect of
DOACs and performed vigorous analyses to examine the
robustness of findings in patients with cancer. A standardized
and comprehensive procedure was conducted to obtain all the
relevant and most updated research and extract the required
information in duplicate with a good level of agreement. Data
analyses and study quality assessment were carried out by fol-
lowing the guidelines and our prespecified protocol. There are
some limitations in our study. First, the majority of the data
were from those trials that provided subgroup analysis results,
which thus impaired the evidence strength. For example, the
imbalance between the patients with and without cancer may
challenge the RCT-design, the small number of patients with
cancer and VTE events prevented covariate adjustment, and the
subgroup analyses were performed postrandomization and
without a prespecified hypothesis. Therefore, the quality of the
entire body of evidence was downgraded even though there
was no significant difference between overall findings (Figures
1 and 2) and sensitivity analysis results that excluded trials that
only provided subgroup analysis data (Table 2). Besides, the
insufficient number of included studies and data may not pro-
vide adequate power to detect significant effect size with
precision. Likewise, the data collected did not allow us to
further explore subgroup difference stratified by sex, renal
dysfunction, individual DOACs, cancer stages, different age
categories, and different dosages of both DOACs and non-
DOACs. In addition, information on the cancer status or sta-
ging may be inaccurate in some trials since these studies were
not designed to the conducted subgroup analysis a priori.
Furthermore, even though no significant subgroup effect was
found in subgroup analyses, the nonsignificant heterogeneity in
the populations (with different cancer status) and the clinical
purposes (prevention or treatment of VTE) should be taken into
careful consideration. Therefore the overall and subgroup find-
ings from this study should be interpreted with caution, which
should not lead to clinical decisions for individual patients in
clinical practice before further high-quality evidence is
available.
In conclusion, the DOACs were found to have a favorable
effect on risk of VTE but a nonsignificantly higher risk of
major bleeding compared with non-DOACs in patients with
cancer. The safety effect of DOACs in patients with cancer,
especially compared with LMWH, requires further evaluation
in adequately powered and designed research studies.
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